Pages that link to "Q44085575"
Jump to navigation
Jump to search
The following pages link to Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol (Q44085575):
Displaying 30 items.
- Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams (Q24631021) (← links)
- Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids (Q24800806) (← links)
- Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy (Q33571277) (← links)
- Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection (Q33790850) (← links)
- Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy (Q34423329) (← links)
- Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir (Q34633457) (← links)
- Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals (Q35579020) (← links)
- Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know (Q35603768) (← links)
- Pharmacogenomics of proton pump inhibitors (Q35689146) (← links)
- Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes (Q35826832) (← links)
- Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity (Q35827674) (← links)
- Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. (Q36068699) (← links)
- Pharmacokinetics of proton pump inhibitors in children (Q36116456) (← links)
- Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo (Q36349377) (← links)
- The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients. (Q37169814) (← links)
- Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration (Q37247655) (← links)
- Update on the Pharmacogenomics of Proton Pump Inhibitors (Q37892538) (← links)
- CYP3A activity: towards dose adaptation to the individual. (Q38763583) (← links)
- Influence of smoking and CYP2C19 genotypes on H. pylori eradication success (Q40320133) (← links)
- Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study (Q40608496) (← links)
- Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects (Q41328717) (← links)
- Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects (Q43615344) (← links)
- The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. (Q44720807) (← links)
- Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity (Q45151697) (← links)
- Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test (Q46621531) (← links)
- Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers (Q46675140) (← links)
- In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease (Q46765974) (← links)
- Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers (Q46788459) (← links)
- Correlations between the enantio- and regio-selective metabolisms of warfarin (Q51248853) (← links)
- Safety and Pharmacokinetics of High-Dose TAS-303 in Healthy Japanese Volunteers: A Single-Center, Single-Blind, Randomized, Placebo-Controlled, Parallel-Group Multiple-Ascending-Dose Study (Q96646481) (← links)